 | | Vol. 16.14 – 11 April, 2024 |
| |
|
|
| Splicing factor 3a subunit 2 (SF3A2), a poorly defined splicing factor, was notably elevated in TNBC tissues and promoted TNBC progression, as confirmed by cell proliferation, colony formation, transwell migration, and invasion assays.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists reported that nuclear phosphoinositides functioned as cofactors that mediated the binding of yes-associated protein 1 (YAP)/TAZ to TEA domain (TEAD) family transcription factors.
[EMBO Journal] |
|
|
|
| Investigators reported the physical, biochemical, and genomic differences between T47D breast cancer cells cultured in 2D and as 3D spheroids.
[EMBO Journal] |
|
|
|
| Researchers examined the efficacy of IRX4204, a highly specific rexinoid, in breast cancer cell lines and pre-clinical models to identify a biomarker for response and potential mechanism of action.
[Clinical Cancer Research] |
|
|
|
| Investigators reported the development of an estrogen receptor-positive (ER+) breast tumor organoid medium that conserved ER expression, estrogen responsiveness, and dependence, as well as sensitivity to endocrine therapy of ER+ patient-derived xenograft organoids.
[Breast Cancer Research] |
|
|
|
| The authors conducted a thorough examination of utrophin (UTRN) using both bioinformatic and in vitro experiments. UTRN expression decreased in breast cancer compared to standard samples, and high UTRN expression correlated with better prognosis.
[Scientific Reports] |
|
|
|
| Scientists demonstrated that up-regulation of YY1 expression was closely associated with breast cancer metastasis, and that high YY1 expression could promote the migratory invasive ability of breast cancer cells.
[Drug Metabolism And Disposition] |
|
|
|
|
| The authors summarize evolving strategies to target BCSCs, which have become a pivotal aspect of therapeutic development. They explore a variety of approaches, including targeting specific tumor surface markers, transporters, heat shock proteins, and critical signaling pathways.
[Medical Oncology] |
|
|
|
|
| Roche announced the approval of the CE Mark for the VENTANA® HER2 Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® may be considered as a targeted treatment.
[F. Hoffmann-La Roche AG (BioSpace)] |
|
|
|
| Researchers at Texas A&M University and the University of Colorado Cancer Center have received a $3.3 million grant from the National Institutes of Health to study how a pair of molecules that regulate certain types of metastatic breast cancer interact with a new drug therapy.
[Texas A&M University] |
|
|
|
|
| May 20, 2024
New York, New York, United States & Online |
|
|
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Ohio State University – Columbus, Ohio, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
